Buy Day today: Neutral (53) Mixed market breadth · no major macro event

Supernus Pharmaceuticals Inc (SUPN)

Healthcare Drug Manufacturers - Specialty & Generic

44.60 $

-2.1% vs. previous close

Closing price · As of: 31. Jul 2026

Supernus Pharmaceuticals Inc (SUPN) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q1 26), "Total Assets" came in at 1,501 million USD. Tick rows to compare them in a chart.

Income Statement Balance Sheet Cash Flow

Annual Quarterly

All figures in millions of USD.

Balance Sheet SUPN
Tick rows to compare them in a chart (up to 4)	Q2 23	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25	Q4 25	Q1 26
Total Assets	1,293	1,285	1,278	1,304	1,316	1,343	1,368	1,347	1,382	1,420	1,453	1,501
Current Assets	424	449	493	544	591	640	686	688	739	594	644	732
Cash	25	95	75	63	52	32	69	116	145	151	128	185
Cash & Short-Term Investments	152	200	255	298	347	403	454	464	523	281	309	384
Receivables	137	142	144	148	152	145	142	146	141	171	188	182
Inventory	91	83	77	75	68	64	54	49	44	79	82	87
Property, Plant & Equipment	14	–	–	–	–	–	–	–	–	–	–	–
Goodwill	117	117	117	117	117	117	117	117	117	119	125	121
Intangible Assets	662	641	600	580	560	540	522	502	481	623	569	550
Total Liabilities	373	373	356	375	358	336	332	317	319	370	391	424
Current Liabilities	253	288	290	315	309	292	292	282	286	331	338	374
Short-Term Debt	8.0	8.5	8.3	9.1	9.7	9.2	6.9	5.9	7.4	11	11	11
Accounts Payable	4.4	3.4	2.0	14	4.6	6.4	4.6	7.1	8.2	8.2	2.7	10
Shareholders' Equity	920	912	922	929	957	1,007	1,036	1,031	1,064	1,050	1,062	1,077
Retained Earnings	497	481	483	483	503	541	556	545	567	522	518	516
Shares Outstanding	55	55	55	56	56	56	56	56	57	57	57	58

Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?

Cookie settings